RothwellP.M.CoullA.J.SilverL.E.Population-based study of event rate, incidence, case-fatality and mortality for all vascular events in all arterial territories (Oxford Vascular Study). Lancet2005; 366:1773–83.
2.
The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group: Tissue plasminogen activator for acute ischemic stroke. N Engl J Med1995; 333:1581–7.
3.
NINDS t-PA Stroke Study Group: Intracerebral hemorrhage after intravenous t-PA therapy for ischemic stroke. Stroke1997; 28:2109–18.
4.
GrahamG.D.: Tissue plasminogen activator for acute ischemic stroke in clinical practice: a meta-analysis of safety data. Stroke2003; 34: 2847–50.
5.
EngelterS.T.BonatiL.H.LyrerP.A.: Intravenous thrombolysis in stroke patients of ≥ 80 versus < 80 years of age - a systematic review across cohort studies. Age Ageing2006; 35:572–80.
6.
ToniD.LorenzanoS.AgnelliG.Intravenous thrombolysis with rtPA in acute ischemic stroke patients aged older than 80 years in Italy. Cerebrovasc Dis2008; 25:129–35.
7.
KimD.FordG.A.KidwellC.S.Intra-arterial thrombolysis for acute stroke in patients 80 and older: a comparison of results in patients younger than 80 years. Am J Neuroradiol2007; 28:159–63.
8.
RinglebP.A.SchwarkC.K$hrmannM.Thrombolytic therapy for acute ischaemic stroke for octogenarians: selection by magnetic resonance imaging improves safety but does not improve outcome. J Neurol Neurosurg Psychiatry2007; 78:690–3.
9.
HackeW.DonnanG.FieschiC.The ATLANTIS, ECASS, and NINDS rt-PA Study Group Investigators. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet2004; 363: 768–74.
